Sarepta Therapeutics, Inc. - Common Stock (NQ:SRPT)

The company's hyperfocus on its core area could continue to be highly lucrative.

Is It Too Late to Buy Sarepta Therapeutics Stock? ↗

February 28, 2024

Companies Reporting Before The Bell • ICL Group (NYSE:ICL) is likely to report quarterly earnings at $0.08 per share on revenue of $1.69 billion.

Earnings Scheduled For February 28, 2024 ↗

February 28, 2024

Via Benzinga

A Preview Of Sarepta Therapeutics's Earnings ↗

February 27, 2024

Via Benzinga

Median Drug Prices For Rare Diseases Hit $300K In 2023, Report Highlights Lack of Clear Rationale Behind Escalating Drug Prices ↗

February 26, 2024

Latest pharmaceutical trends in the U.S. as drug prices surged 35% in 2023. Uncover insights into the industry's focus on rare diseases, escalating costs, and the impact on FDA-approved drugs.

Via Benzinga

Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2023 Financial Results

February 21, 2024

FDA Fast-Tracks Review Of Sarepta's Groundbreaking Muscular Dystrophy Treatment With $1B Market In Sight ↗

10 Health Care Stocks Whale Activity In Today's Session ↗

February 19, 2024

Via Benzinga

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

February 19, 2024

Via Benzinga

In-Depth Examination Of 13 Analyst Recommendations For Sarepta Therapeutics ↗

February 15, 2024

Via Benzinga

Assessing Sarepta Therapeutics: Insights From 12 Financial Analysts ↗

January 30, 2024

Via Benzinga

February 16, 2024

Sarepta's Elevidys efficacy supplement accepted for Duchenne muscular dystrophy treatment expansion, potential $1 billion yearly opportunity. FDA review goal: June 21, 2024.

Via Benzinga

Why DoorDash Shares Are Trading Lower By Around 12%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗

February 16, 2024

Shares of DoorDash, Inc. (NASDAQ: DASH) fell sharply in today’s session as the company reported mixed financial results for its fourth quarter.

Via Benzinga

Why Sarepta Therapeutics Stock Is Soaring Today ↗

February 16, 2024

The biotech just scored a big FDA win with an even bigger one potentially coming by June.

Applied Materials Posts Upbeat Earnings, Joins Texas Roadhouse, Vulcan Materials And Other Big Stocks Moving Higher On Friday ↗

February 16, 2024

U.S. stocks were lower, with the Dow Jones index falling more than 100 points on Friday.

Via Benzinga

Topics Stocks

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

February 16, 2024

Via Benzinga

Sarepta Therapeutics Announces U.S. FDA Acceptance of an Efficacy Supplement to Expand the ELEVIDYS Indication

February 16, 2024

No need to break the bank to invest in promising stocks.

2 Magnificent Growth Stocks to Buy With $500 ↗

February 15, 2024

Gene therapy treatments have been making major headlines as advances in gene editing have gone mainstream thanks to the advent of CRISPR/Cas-9 technology.

Gene therapy: Why does it cost millions for a single treatment?

February 15, 2024

Gene Therapy Player REGENXBIO's RGX-121 Marks Success In Trial, Yet Faces Challenges In A Crowded Market: Analyst ↗

February 12, 2024

Insights from Wedbush analysts about the clinical effectiveness of REGENXBIO's RGX-202, market potential, and challenges posed by competitors like Sarepta Therapeutics and Pfizer.

Via Benzinga

1 of Sarepta Therapeutics' Competitors Just Got Hammered. Will It Help the Stock? ↗

February 11, 2024

Bad news for one player does not always equal good news for another.

A look at the bearish analog structure that the S&P 500 could be unfolding and the 3 warning signs you can't ignore.

Decoding Bearish Analog And The Warning Signs You Can't Ignore ↗

February 07, 2024

Via Talk Markets

Topics Stocks

The Top 25 Stocks to Buy Immediately According to AI: February 2024 Edition ↗

February 06, 2024

Some of the best stocks to buy in February according to MarketMaster AI suggest that a major economic recovery is underway.

Via InvestorPlace

Topics Artificial Intelligence

PepGen soars on Sarepta Therapeutics’ Duchenne drug phase 2 data

February 06, 2024

PepGen stock is moving higher on expectations of positive Phase 2 clinical trial results for its Duchenne muscular dystrophy (DMD) gene therapy

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

January 31, 2024

Sarepta Therapeutics' Next-Gen Duchenne Muscular Therapy Shows Efficacy At Less Frequent Dosing ↗

January 29, 2024

Sarepta Therapeutics unveils results from MOMENTUM study's Phase 2 trial for SRP-5051, a next-gen PPMO treatment targeting Duchenne muscular dystrophy.

Via Benzinga

Sarepta Therapeutics Announces Positive Data from Part B of MOMENTUM, a Phase 2 Study of SRP-5051 in Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 51

January 29, 2024

Markets continued to push to new all-time highs, setting the stage for big tech earnings, which will happen next week; here are the top stories from this week.

MarketBeat Week in Review: 1/22 - 1/26

January 27, 2024

There's more to stock picking than comparing risk and reward. Finding the right position size for a particular stock is also important.

Topics Economy

Got $3,000? 3 Growth Stocks to Double Up On Right Now ↗

January 26, 2024

It's always tough to be compared to a giant.

Could Sarepta Therapeutics Become the Next Vertex Pharmaceuticals? ↗

January 25, 2024

Sarepta Therapeutics Inc. (NASDAQ: SRPT) is a leading commercial-stage biotech focused on developing precision gene therapy treatments for rare diseases.

Sarepta Therapeutics Inc.: Why it's a rising gene therapy star

January 23, 2024